Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial.

Detalles Bibliográficos
Autores principales: Rosales Renteria, Luis Alejandro, Jaramillo-Ramírez, Hiram, Calderón-Mendieta, Francisco, Camacho-Escobedo, Jesús, Avendaño-Reyes, José Manuel, López-Rubio, Diana Laura, Araiza, Adrián Sández, Reyes-Higuera, Gisel Estefania, Soto-González, Dulce Renée, Arzola-Renteria, Erikc Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:
POSTER PRESENTATIONS: Thursday 23 June: Cirrhosis and its complications: ACLF and Critical illness
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252357/
http://dx.doi.org/10.1016/S0168-8278(22)01067-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252357/
http://dx.doi.org/10.1016/S0168-8278(22)01067-4

Ejemplares similares